天弘国证生物医药ETF发起式联接A(011040)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-70,845,561.42 |
60,622,845.45 |
29,074,596.44 |
-281,085,403.20 |
| 利息合计 |
476,588.08 |
911,823.45 |
453,973.09 |
978,732.22 |
| 其中：存款利息收入 |
476,588.08 |
911,823.45 |
453,973.09 |
978,732.22 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-35,949,037.36 |
-180,872,233.46 |
-114,645,146.79 |
-93,755,813.15 |
| 其中：股票投资收益 |
-2,145,601.73 |
-3,950,633.46 |
-3,642,653.68 |
-19,554,648.93 |
| 基金投资收益 |
-33,891,482.86 |
-177,230,566.63 |
-111,148,487.33 |
-74,740,171.21 |
| 债券投资收益 |
- |
3,208.01 |
1,560.62 |
38,809.89 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
88,047.23 |
305,758.62 |
144,433.60 |
500,197.10 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-35,908,802.08 |
240,145,964.83 |
143,146,990.91 |
-189,258,922.94 |
| 其他收入 |
535,689.94 |
437,290.63 |
118,779.23 |
950,600.67 |
| 费用 |
1,216,909.65 |
2,396,781.37 |
1,203,105.55 |
2,487,200.65 |
| 管理人报酬 |
181,564.76 |
354,341.86 |
183,372.57 |
418,523.76 |
| 基金托管费 |
36,312.89 |
70,868.44 |
36,674.51 |
83,704.73 |
| 销售服务费 |
908,284.03 |
1,788,571.07 |
892,310.50 |
1,801,972.16 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
90,747.97 |
183,000.00 |
90,747.97 |
183,000.00 |
| 利润总额 |
-72,062,471.07 |
58,226,064.08 |
27,871,490.89 |
-283,572,603.85 |
微信公众号
证券之星APP
基本资料
